Genzyme, Neozyme II Corp. deal

The companies signed a definitive acquisition agreement under which GENZ will acquire the cystic fibrosis R&D spin-off for $45 per NIIUF unit. GENZ, through a wholly-owned subsidiary, commenced a cash...